Accessible Search Form           Advanced Search

Adrian Wiestner, M.D., Ph.D.


Principal Investigator thumbnail image

Adrian Wiestner
Senior Investigator

P: +1 301 594 6855

Full Publications Listing

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner A.
Blood. 2012 Dec 6;120(24):4684-91.
[Text Abstract on PubMed]

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A.
Blood. 2012 Oct 25;120(17):3501-9.
[Text Abstract on PubMed]

Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.
Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A, Stamatopoulos K, Beà S, Campo E.
Cancer Res. 2012 Oct 15;72(20):5307-16.
[Text Abstract on PubMed]

Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia.
Zhu P, Degheidy HA, Marti GE, Li S, Abbasi F, Wiestner A, Amstutz P, Tang CM.
Leuk. Lymphoma. 2012 Aug 14.
[Text Abstract on PubMed]

Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.
Royo C, Navarro A, Clot G, Salaverria I, Giné E, Jares P, Colomer D, Wiestner A, Wilson WH, Vegliante MC, Fernandez V, Hartmann EM, Trim N, Erber WN, Swerdlow SH, Klapper W, Dyer MJ, Vargas-Pabón M, Ott G, Rosenwald A, Siebert R, López-Guillermo A, Campo E, Beà S.
Leukemia. 2012 Aug;26(8):1895-8.
[Text Abstract on PubMed]

Targeting malignant B cells with an immunotoxin against ROR1.
Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C.
MAbs. 2012 May-Jun;4(3):349-61.
[Text Abstract on PubMed]

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.
Clin. Cancer Res. 2012 Apr 1;18(7):1979-91.
[Text Abstract on PubMed]

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP.
J. Immunol. 2012 Apr 1;188(7):3532-41.
[Text Abstract on PubMed]

Combined normal donor and CLL: Single tube ZAP-70 analysis.
Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Cytometry B Clin Cytom. 2012 Mar;82(2):67-77.
[Text Abstract on PubMed]

Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia.
Biancotto A, Dagur PK, Fuchs JC, Wiestner A, Bagwell CB, McCoy.
Mod. Pathol. 2012 Feb;25(2):246-59.
[Text Abstract on PubMed]

TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation.
Vire B, David A, Wiestner A.
J. Immunol. 2011 Oct 15;187(8):4040-50.
[Text Abstract on PubMed]

Inflammation, TNFa and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.
Aue G, Nelson Lozier J, Tian X, Cullinane AM, Soto S, Samsel L, McCoy P, Wiestner A.
Am. J. Hematol. 2011 Oct;86(10):835-40.
[Text Abstract on PubMed]

Methodological comparison of two anti-ZAP-70 antibodies.
Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Cytometry B Clin Cytom. 2011 Sep;80(5):300-8.
[Text Abstract on PubMed]

Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.
Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Cytometry B Clin Cytom. 2011 Sep;80(5):309-17.
[Text Abstract on PubMed]

Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.
Herishanu Y, Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, Bern S, Keyvanfar K, Lee E, Wilson W, Wiestner A.
Leuk. Lymphoma. 2011 Sep;52(9):1758-69.
[Text Abstract on PubMed]

Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.
Clin. Cancer Res. 2011 Aug 1;17(15):5101-12.
[Text Abstract on PubMed]

What do pediatric residents know about malpractice?
Roy AD, Chen L, Santucci K.
Pediatr Emerg Care. 2011 Jul;27(7):586-90.
[Text Abstract on PubMed]

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.
Blood. 2011 Jan 13;117(2):563-74.
[Text Abstract on PubMed]

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A.
Blood. 2011 Jan 13;117(2):542-52.
[Text Abstract on PubMed]

Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C.
PLoS ONE. 2011;6(6):e21018.
[Text Abstract on PubMed]

Permanent cerebrospinal fluid diversion in subarachnoid hemorrhage: Influence of physician practice style.
Esposito DP, Goldenberg FD, Frank JI, Ardelt AA, Roitberg BZ.
Surg Neurol Int. 2011;2:117.
[Text Abstract on PubMed]

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.
Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S.
Blood. 2010 Aug 19;116(7):1025-34.
[Text Abstract on PubMed]

Unexpected detection of monoclonal B-cell lymphocytosis in a HLA-matched sibling donor on the day of allogeneic stem cell transplantation for a patient with chronic lymphocytic leukaemia: clinical outcome.
Herishanu Y, Eshel R, Kay S, Rothman R, Njuguna N, Perry C, Shpringer M, Wiestner A, Polliack A, Naparstek E.
Br. J. Haematol. 2010 Jun;149(6):905-7.
[Text Abstract on PubMed]

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, Wiestner A.
Haematologica. 2010 Feb;95(2):329-32.
[Text Abstract on PubMed]

The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
Wang Q, Shinkre BA, Lee JG, Weniger MA, Liu Y, Chen W, Wiestner A, Trenkle WC, Ye Y.
PLoS ONE. 2010;5(11):e15479.
[Text Abstract on PubMed]

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, Keyvanfar K, Gibellini F, Valdez J, Boss C, Samsel L, McCoy, Wilson WH, Pittaluga S, Wiestner A.
Haematologica. 2009 Sep;94(9):1266-73.
[Text Abstract on PubMed]

Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes.
Tiedt R, Coers J, Ziegler S, Wiestner A, Hao-Shen H, Bornmann C, Schenkel J, Karakhanova S, de Sauvage FJ, Jackson CW, Skoda RC.
Blood. 2009 Feb 19;113(8):1768-77.
[Text Abstract on PubMed]

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, Ron D, Chen W, Trenkle W, Wiestner A, Ye Y.
Proc. Natl. Acad. Sci. U.S.A. 2009 Feb 17;106(7):2200-5.
[Text Abstract on PubMed]

Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
Ahmad E, Steinberg SM, Goldin L, Hess CJ, Caporaso N, Kreitman RJ, Wiestner A, Wilson W, White T, Marti G, Stetler-Stevenson M.
Cytometry B Clin Cytom. 2008 Jul;74(4):221-6.
[Text Abstract on PubMed]

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, Lai R, Wiestner A.
Leuk. Lymphoma. 2008 Apr;49(4):798-808.
[Text Abstract on PubMed]

Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A, Rader C.
Clin. Cancer Res. 2008 Jan 15;14(2):396-404.
[Text Abstract on PubMed]

Genetically identical twin transplantation for chronic lymphocytic leukemia.
Pavletic SZ, Zhou G, Sobocinski K, Marti G, Doney K, DiPersio J, Feremans W, Foroni L, Goodman S, Prentice G, LeMaistre C, Bandini G, Ferrant A, Jacobsen N, Khouri I, Gale RP, Wiestner A, Giralt S, Montserrat E, Chan WC, Bredeson C, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee.
Leukemia. 2007 Dec;21(12):2452-5.
[Text Abstract on PubMed]

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.
Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM.
Blood. 2007 Jun 1;109(11):4599-606.
[Text Abstract on PubMed]

Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Robles AI, Wright MH, Gandhi B, Feis SS, Hanigan CL, Wiestner A, Varticovski L.
Clin. Cancer Res. 2006 Nov 1;12(21):6547-56.
[Text Abstract on PubMed]

Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.
Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally M, Williams ME.
Leuk. Res. 2006 Apr;30(4):449-57.
[Text Abstract on PubMed]

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A.
Blood. 2005 Mar 15;105(6):2473-9.
[Text Abstract on PubMed]

More ZAP for chronic lymphocytic leukemia (CLL).
Wiestner A.
Blood. 2005 Mar 1;105(5):1839-40.
[Text Abstract on PubMed]

Rituximab for autoimmune haemophilia: a proposed treatment algorithm.
Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB, Wiestner A, Schechter GP.
Haemophilia. 2005 Jan;11(1):13-9.
[Text Abstract on PubMed]

Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA.
Clin. Cancer Res. 2004 Feb 1;10(3):1047-56.
[Text Abstract on PubMed]

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG.
Lancet. 2004 Jan 10;363(9403):105-11.
[Text Abstract on PubMed]

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM.
Proc. Natl. Acad. Sci. U.S.A. 2003 Aug 19;100(17):9991-6.
[Text Abstract on PubMed]

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
Blood. 2003 Jun 15;101(12):4944-51.
[Text Abstract on PubMed]

Rituximab in the treatment of acquired factor VIII inhibitors.
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP.
Blood. 2002 Nov 1;100(9):3426-8.
[Text Abstract on PubMed]

Howell Jolly bodies and a history of home-made bread.
Wiestner A, Tichelli A, Gratwohl A.
Br. J. Haematol. 2001 Aug;114(2):247.
[Text Abstract on PubMed]

Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia.
Wiestner A, Padosch SA, Ghilardi N, Cesar JM, Odriozola J, Shapiro A, Skoda RC.
Br. J. Haematol. 2000 Jul;110(1):104-9.
[Text Abstract on PubMed]

Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene.
Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC.
Br. J. Haematol. 1999 Nov;107(2):310-6.
[Text Abstract on PubMed]

Genomic organisation of the human chordin gene and mutation screening of candidate Cornelia de Lange syndrome genes.
Smith M, Herrell S, Lusher M, Lako L, Simpson C, Wiestner A, Skoda R, Ireland M, Strachan T.
Hum. Genet. 1999 Jul-Aug;105(1-2):104-11.
[Text Abstract on PubMed]

Thrombopoietin production is inhibited by a translational mechanism.
Ghilardi N, Wiestner A, Skoda RC.
Blood. 1998 Dec 1;92(11):4023-30.
[Text Abstract on PubMed]

The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia.
Harrison CN, Gale RE, Wiestner AC, Skoda RC, Linch DC.
Br. J. Haematol. 1998 Sep;102(5):1341-3.
[Text Abstract on PubMed]

An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia.
Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC.
Nat. Genet. 1998 Jan;18(1):49-52.
[Text Abstract on PubMed]

Defective STAT signaling by the leptin receptor in diabetic mice.
Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, Skoda RC.
Proc. Natl. Acad. Sci. U.S.A. 1996 Jun 25;93(13):6231-5.
[Text Abstract on PubMed]

Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets.
Stoffel R, Wiestner A, Skoda RC.
Blood. 1996 Jan 15;87(2):567-73.
[Text Abstract on PubMed]

Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections.
Widmer AF, Wiestner A, Frei R, Zimmerli W.
Antimicrob. Agents Chemother. 1991 Apr;35(4):741-6.
[Text Abstract on PubMed]